Skip to main content
Premium Trial:

Request an Annual Quote

Aventis, Millennium in $450 M Deal

Premium

Aventis Pharma, the pharmaceutical unit of Aventis, has said it would pay Millennium Pharmaceuticals $450 million for a stake in the company as well as for the rights to its drug discovery technologies.

 

Under the terms of the deal, Aventis will pay Millennium of Cambridge, Mass., up to $200 million over a five-year period in exchange for the rights to its technologies. Aventis of Frankfurt, will also buy up to $250 million in Millennium’s common stock. A $150 million stock purchase is to be made at the closing of the deal and two $50 million purchases will be made in 2001.

 

The two companies said they would work together to develop new technologies along with anti-inflammatory drugs aimed at treating rheumatoid arthritis, asthma and chronic obstructive pulmonary disease, multiple sclerosis, and inflammatory bowel disease.

 

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.